[關(guān)鍵詞]
[摘要]
目的 觀察丹參注射液與依達(dá)拉奉右莰醇在急性腦梗死中的聯(lián)用效果。方法 選取2021年10月—2024年9月巴彥淖爾市醫(yī)院收治的122例急性腦梗死患者的病例資料進(jìn)行回顧性分析,隨機(jī)分為對(duì)照組和治療組,每組各61例。對(duì)照組靜脈滴注依達(dá)拉奉右莰醇注射用濃溶液,15 mL/次,溶于100 mL的生理鹽水,滴注時(shí)間<30 min,2次/d。在對(duì)照組基礎(chǔ)上,治療組靜脈滴注丹參注射液,20 mL/次,溶于250 mL的生理鹽水,1次/d。兩組患者連續(xù)用藥14 d。觀察兩組患者臨床療效,比較治療前后兩組患者美國(guó)國(guó)立衛(wèi)生研究院卒中量表(NIHSS)、Fugl-Meyer上肢運(yùn)動(dòng)功能評(píng)定量表(U-FMA)和簡(jiǎn)版腦卒中患者專門生存質(zhì)量量表(SV-SS-QoL)評(píng)分,及搏動(dòng)指數(shù)(PI)、阻力指數(shù)(RI)、平均血流速度(Vm)、收縮期峰值血流速度(Vs)、平均血小板體積/血小板計(jì)數(shù)比值(MPV/PLT)、紅細(xì)胞分布寬度變異系數(shù)(RDW-CV)和C反應(yīng)蛋白(CRP)水平。結(jié)果 治療后,對(duì)照組總有效率為83.61%,治療組為95.08%,兩組患者比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組NIHSS評(píng)分顯著降低,而U-FMA和SV-SS-QoL評(píng)分顯著升高(P<0.05),且治療組NIHSS、U-FMA和SV-SS-QoL評(píng)分明顯好于對(duì)照組(P<0.05)。治療后,兩組患者患側(cè)大腦中動(dòng)脈的PI、RI、MPV/PLT、RDW-CV和CRP均低于同組治療前,而Vm、Vs則顯著升高(P<0.05),且治療組這些指標(biāo)明顯均好于對(duì)照組(P<0.05)。結(jié)論 丹參注射液聯(lián)合依達(dá)拉奉右莰醇治療急性腦梗死能有效控制腦血流動(dòng)力學(xué)異常和炎癥反應(yīng),抑制血栓形成,降低神經(jīng)功能損害,促進(jìn)肢體運(yùn)動(dòng)功能恢復(fù)。
[Key word]
[Abstract]
Objective To observe the combined effect of Danshen Injection and edaravone dexmedetomidine in acute cerebral infarction. Methods The clinical data of patients (122 cases) with acute cerebral infarction in Bayannur Hospital from October 2021 to September 2024 were analyzed retrospectively, and they were randomly divided into control and treatment group, each group had 61 cases. Patient in the control group were iv administered with Edaravone and Dexborneol Concentrated Solution for injection, 15 mL/time was added into normal saline 100 mL, the treatment time was less than 30 min, twice daily. Patient in the treatment group were iv administered with Danshen Injection on the basis of the control group, 20 mL/time was added into normal saline 250 mL, once daily. Patient in two groups were treated for 14 d. After treatment, the clinical evaluations were evaluated, and the scores of NIHSS, U-FMA and SV-SS-QoL, and the levels of PI, RI, Vm, Vs, MPV/PLT, RDW-CV and CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate was 83.61% in the control group and 95.08% in the treatment group, the difference between the two groups was statistically significant (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased, while the U-FMA and SV-SS-QoL scores were significantly increased (P < 0.05), and these scores in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, PI, RI, MPV/PLT, RDW-CV and CRP in the affected middle cerebral artery in two groups were lower than before treatment, while Vm and Vs were significantly increased (P < 0.05), and these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Edaravone and dexmedetomidine combined with Danshen Injection in treatment of acute cerebral infarction can effectively control cerebral hemodynamic abnormalities and inflammatory reactions, inhibit thrombosis, reduce neurological damage, and promote the recovery of limb motor function.
[中圖分類號(hào)]
R971
[基金項(xiàng)目]
巴彥淖爾市醫(yī)院科技創(chuàng)新激勵(lì)計(jì)劃項(xiàng)目(2023002)